Mutation in the Unrearranged PML Allele Confers Resistance to Arsenic Trioxide in Acute Promyelocytic Leukemia
Arsenic trioxide (ATO) is able to selectively target and degrade the disease-causing PML::RARα (P/R) oncoprotein in acute promyelocytic leukemia (APL) for curing the disease. However, some relapsed patients develop resistance to ATO due to mutations in the promyelocytic leukemia (PML) part of the PM...
Saved in:
| Main Authors: | Pei-Han Yu, Chen-Ying Zhu, Yuan-Yuan Kang, Hua Naranmandura, Chang Yang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
American Association for the Advancement of Science (AAAS)
2025-01-01
|
| Series: | Research |
| Online Access: | https://spj.science.org/doi/10.34133/research.0696 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effects of arsenic on the topology and solubility of promyelocytic leukemia (PML)-nuclear bodies.
by: Seishiro Hirano, et al.
Published: (2022-01-01) -
Arsenic Trioxide Treatment during Pregnancy for Acute Promyelocytic Leukemia in a 22-Year-Old Woman
by: Claire Cochet, et al.
Published: (2020-01-01) -
Comparison of newly diagnosed and relapsed patients with acute promyelocytic leukemia treated with arsenic trioxide: insight into mechanisms of resistance.
by: Ezhilarasi Chendamarai, et al.
Published: (2015-01-01) -
Severe acute axonal neuropathy following treatment with arsenic trioxide for acute promyelocytic leukemia: a case report
by: Marcus Kuhn, et al.
Published: (2016-05-01) -
A phase II study evaluating the role of bortezomib in the management of relapsed acute promyelocytic leukemia treated upfront with arsenic trioxide
by: Uday Kulkarni, et al.
Published: (2020-04-01)